Pharmaceuticals & Biotech Swedish Community

In 2026, the story is no longer about how many companies Swedencare can buy, but how effectively it can scale its existing brands (ProDen PlaqueOff and NaturVet) into global Big Box retail and e-commerce The Pet Humanization Play Swedencare's narrative rests on three pillars: The Global Brand Portfolio: Moving from a single product company to a diversified pet health giant. The story is about cross-selling, taking a successful dental product from Sweden and putting it in 2,000 Walmart stores in the US The Channel Pivot: Swedencare is taking direct control of its destiny by moving Amazon sales inhouse and entering Big Box retail like Walmart, CVS etc.Read more

Oncolytics Biotech is pushing a new immune-based cancer treatment that’s showing encouraging early signs in some of the hardest-to-treat cancers, including pancreatic and certain digestive cancers. A recent green light from a German regulator and fresh conference results hint at momentum, but the big question is whether later trial readouts can hold up.Read more

Catalysts Most Immediate Catalyst (1–2 Years): Strong Oncology Portfolio Growth: AstraZeneca’s cancer drugs Tagrisso, Imfinzi, Enhertu, and Calquence continue gaining market share, driving double-digit revenue growth in oncology. Respiratory & Cardiovascular Expansion: New approvals and label expansions in Farxiga (diabetes/heart failure) and Tezspire (severe asthma) can drive meaningful sales upside.Read more

BioArctic’s Alzheimer’s drug royalties are growing, but the story may hinge on whether health systems keep paying for expensive long-term treatments and how quickly access opens up across countries. With much of the upside tied to a small set of programs and big partners, a setback in trials, safety, or partnership priorities could quickly change the outlook.Read more

Hansa Biopharma may be closer to a faster growth phase than many expect as more transplant centers start using IDEFIRIX in routine care and regulators move it toward broader access. But the story also hinges on one main product while losses, policy shifts, and tougher competition could derail momentum.Read more

Cinclus Pharma is betting big on a single new treatment for severe acid reflux, and growing diagnosis rates plus early partner deals could open the door to much larger markets. But with expensive late-stage trials still ahead and rivals already moving fast, the upside depends heavily on whether its lead drug delivers and wins adoption.Read more

Bonesupport is seeing its CERAMENT G product pick up speed in the U.S., with doctors coming back to use it again and finding new ways to apply it. Upcoming U.S. approvals and insurance payment changes could add another tailwind, but higher selling costs, currency swings, and uneven access in parts of Europe could still hold results back.Read more

Catalysts About Mendus Mendus is a biotech company developing vididencel, an immunotherapy aimed at improving outcomes in myeloid blood cancers such as AML and CML, with a partnered ovarian cancer program. What are the underlying business or industry changes driving this perspective?Read more

Key Takeaways Recovery in IVF procedure volume and expansion in key regions will drive organic revenue growth and margin improvement as market conditions stabilize. Product innovation, increased reimbursement support, and automation investments will enhance customer retention and support long-term international sales growth.Read more